Talecris Biotherapeutics
Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP
Published in Medical Letter on the CDC and FDA, October 12th, 2008
A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah. The study authors concluded that "further studies in CIDP are warranted to more clearly define the duration of treatment required to achieve and maintain maximal response to IVIG therapy."
The study of CIDP, a neurological...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Massachusetts General Hospital
Study confirms benefit of combination therapy for Alzheimer's disease - Alzheimer Disease
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease - Anxiety Disorders
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression - Celsion Corporation
Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial - Endoscopy
Study Published in Gastrointestinal Endoscopy Features Computer-Assisted Personalized Sedation (CAPS) - Obesity and Diabetes
First Reported Head-to-Head Study Showed BYETTAŽ (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia (sitagliptin) in Patients With Type 2 Diabet - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
